Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company
focusing on non-antibiotic anti-infectives, announced today that
CEOLIVE.TV, an online service that delivers news about companies to
investors, has highlighted NovaBay's important advance in eye care
interview with Kathryn Najafi-Tagol, M.D., the founder and director
of the Eye
Institute of Marin in San Rafael, California.
Kathryn Najafi-Tagol, M.D., the founder and director of the Eye Institute of Marin in San Rafael, California. (Photo: Business Wire)
In the interview with Mike Elliott of CEOLIVE.TV, Dr. Najafi-Tagol
described the success she's been having with NovaBay's new i-LidTM
"The product came out of the frustration I was having with treating a
very common eye condition called blepharitis," said Dr.
Najafi-Tagol. "More than half of the patients who come in for the
treatment of glaucoma, cataract, or macular degeneration also have
blepharitis or meibomian gland dysfunction," she explains. Blepharitis
is typically caused by the growth of staphylcocci bacteria on
eyelids, causing swelling, redness, inflammation, irritation, and a
crusty build-up. The bacteria can also produce toxins that break down
secretions from the meibomian gland, leading to meibomian gland
dysfunction and dry eye syndrome. "These are all very serious
conditions," she said.
For years, physicians have been treating these patients with existing
eyelid hygiene products such as wipes, antibiotics, and steroids.
However, many patients develop chronic inflammation and damage to their
eyelids and glands despite treatment. Some patients suffer from
blepharitis chronically for many years. Moreover, many traditional
treatments have caused concern about creating antibiotic-resistant
bacteria or increasing pressure in the eye. "Doctors needed something
etter," Dr. Najafi-Tagol said.
So she turned to i-Lid Cleanser, which she helped develop as an advisor
to NovaBay. It is a stable pure form of hypochlorous
solution (HOCl) in saline, a substance naturally made by the body's
immune system as a first defense against microbial invaders. Laboratory
tests show that i-Lid Cleanser not only kills bacteria, it also
neutralizes the toxins produced by bacteria-and is safe as a skin
Dr. Najafi-Tagol now uses i-Lid Cleanser extensively in her practice as
part of the treatment of blepharitis, and to clean eyes of any debris
and crusting for 5 days before cataract or glaucoma surgery. For her
patients, i-Lid Cleanser has brought major improvements in their quality
of life, as described by several patients in this video.
Dr. Najafi-Tagol isn't alone in her opinion of i-Lid Cleanser. Professor
Christine W. Sindt O.D., Optometrist and Clinical Associate
Professor of Ophthalmology and Visual Sciences at the University of
Iowa, describes i-Lid Cleanser as the "21st Century lid and
lash hygiene product" in a May
issue of RCCL (Review of Cornea and Contact Lenses page 7). "Baby
shampoos as well as some eyelid cleansers contain chemicals such as
cocamidopropyl betaine, a surfactant and lathering agent that may cause
eyelid dermatitis," says Prof. Sindt.
Because so many patients suffer from these eye conditions, Dr.
Najafi-Tagol believes the potential market for i-Lid Cleanser is "huge."
For NovaBay i-Lid Cleanser purchasing information, please contact:
This release contains forward-looking statements and opinions, which
are based upon management's current expectations, assumptions,
estimates, projections and beliefs, and also those of unaffiliated
individuals. These statements include, but are not limited to,
statements regarding the general effectiveness of NovaBay's products,
potential market size for NovaBay products, and the quoted opinions of
NovaBay products by certain physicians. The words "believes," "show,"
and "can" are intended to identify these forward-looking statements. Forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause actual results or achievements to be materially
different and adverse from those expressed in or implied by the
forward-looking statements. Factors that might cause or contribute to
such differences include, but are not limited to, risks and
uncertainties relating to the actual effectiveness of NovaBay products
and unexpected adverse side effects or inadequate therapeutic efficacy
of i-Lid Cleanser. Other risks relating to NovaBay and its products,
including risks that could cause results to differ materially from those
projected in the forward-looking statements in this press release, are
detailed in NovaBay's latest Form 10-K and Form 10-Q filings with the
Securities and Exchange Commission, especially under the heading "Risk
Factors." The forward-looking statements in this release speak only as
of this date, and NovaBay disclaims any intent or obligation to revise
or update publicly any forward-looking statement except as required by
Stay informed on NovaBay's progress:
Like us on FacebookFollow
us on TwitterConnect
with NovaBay on LinkedInJoin
us on Google+Visit
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140703005103/en/
[ Back To NFVZone's Homepage ]